Home › Calculator › ADOCY Dividend Calculator 2026
ADOCY Dividend DRIP Calculator 2026
16.95% YieldHealthcareAdocia S.A. · OTC
Price: $11.80 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ADOCY pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ADOCY snowball 📈
$10,000 in ADOCY → $296.45M in 10 years · $23,866,784.21/month
About Adocia S.A. (ADOCY) — Dividend Analysis 2026
Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders. Central to its work is the exclusive BioChaperone technological platform, engineered to significantly enhance the performance characteristics of therapeutic proteins. Its robust clinical pipeline features several advanced candidates: Insulin-based treatments: Including BioChaperone Lispro U100 and U200, which are ultra-fast-acting versions derived from rapid insulin lispro; BioChaperone Combo, combining long-acting insulin glargine with rapid-acting insulin lispro; and BioChaperone LisPram, which pairs prandial insulin with pramlintide. Hypoglycemia treatment: BioChaperone Glucagon, an aqueous human glucagon solution specifically designed to manage severe low blood sugar episodes. Other: M1Pram, a derivative combining insulin glargine and pramlintide. The preclinical development programs further expand into bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a co-formulation of insulin glargine and a GLP-1 receptor analogue. Additionally, its preclinical portfolio targets obesity with multi-hormonal products like BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a tripartite blend of pramlintide, glucagon, and exenatide. Adocia has forged a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. for the development and market introduction of BioChaperone Lispro and BioChaperone Combo across China, other parts of Asia, and the Middle East. Established in 2005, the company maintains its headquarters in Lyon, France.
Compare ADOCY with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ADOCY DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ADOCY position with:
🌍 ADOCY Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ADOCY.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 16.95% | 14.15% | $1,695 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 14.41% | 11.61% | $1,441 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 13.56% | 10.76% | $1,356 / yr |
| 🇬🇧 UK ISA | 0% | 16.95% | 14.15% | $1,695 / yr |
| 🇬🇧 UK Taxable | 8.75% | 15.47% | 12.67% | $1,547 / yr |
| 🇨🇦 TFSA | 0% | 16.95% | 14.15% | $1,695 / yr |
| 🇨🇦 CA Taxable | 25% | 12.71% | 9.91% | $1,271 / yr |
| 🇦🇺 Super (pension) | 15% | 14.41% | 11.61% | $1,441 / yr |
| 🇦🇺 AU Taxable | 30% | 11.86% | 9.06% | $1,186 / yr |
| 🇩🇪 DE Taxable | 26.375% | 12.48% | 9.68% | $1,248 / yr |
| 🇫🇷 FR Taxable | 30% | 11.86% | 9.06% | $1,186 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ADOCY Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ADOCY Dividend Payment Schedule
ADOCY pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ADOCY vs Healthcare Benchmarks
How ADOCY compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADOCY sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ADOCY Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADOCY dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Adocia S.A. (ADOCY) is currently trading at $11.80, 10% below its 52-week high. The current dividend yield is 16.95% based on an annual payout of $2.00 per share.
ADOCY (Adocia S.A.) — 16.95% Dividend Yield Analysis
Adocia S.A. (ADOCY) is a healthcare stock currently trading at $11.80 with a dividend yield of 16.95%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (16.95%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.